Company intelligence / Profile preview
Biopharmaceutical Research Company
United Statesbiopharmaresearchco.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
BRC has received FDA Orphan Drug Designation for BRC-002 for Complex Regional Pain Syndrome. The company has begun dosing patients in investigator-initiated clinical trials for both BRC-001 (breast cancer supportive care) and BRC-002 (CRPS). They recently had a successful Type C CMC meeting with the FDA, advancing clinical development of multiple therapeutic candidates[2].
- Therapeutic areas
- OncologyRheumatologyNeurology
- Modalities
- Cannabinoid therapeuticsPoly-cannabinoids
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
City of Hope
Beyond the preview
Go deeper on Biopharmaceutical Research Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biopharmaceutical Research Company.